Computer Software Assurance Is Here: Why Medical Device Manufacturers Should Rethink QMS Software Validation
FDA’s Computer Software Assurance guidance supports a risk-based approach to production and quality system software. Learn what medical device manufacturers should update in their eQMS, ERP, MES, LIMS, and validation programs.
By Melita Ball
Computer Software Assurance, commonly called CSA, is changing how medical device manufacturers should think about software used in production and the quality system.
For years, many companies approached software validation with the same reflex: create large validation binders, test every feature the same way, document every step in heavy detail, and hope the package satisfied auditors. The result was often slow, expensive, and oddly risky. Teams spent too much energy documenting low-risk functions and not enough energy understanding where software failure could actually affect device quality, patient safety, data integrity, or regulatory records.
FDA's CSA guidance supports a more practical approach. Manufacturers still need objective evidence that software is fit for its intended use. The difference is that the assurance effort should be based on risk, intended use, and the impact of the software function.
The short answer
CSA is not validation-lite. It is risk-based confidence that the right software functions work for the right regulated purpose.
That distinction matters. Manufacturers should not treat CSA as a way to do less. They should treat it as a way to aim quality effort better.
Why CSA matters now
Most life sciences companies rely on software to run regulated work. That includes document control, training, CAPA, complaints, supplier quality, equipment maintenance, production records, calibration, inspection, inventory, labeling, clinical data, dashboards, and reporting.
At the same time, many companies are still operating with a patchwork of systems: one eQMS, one ERP, one spreadsheet tracker, one shared drive, one training system, one supplier portal, and several unofficial workarounds. Every system creates validation, access control, data integrity, change control, and audit trail questions.
CSA gives manufacturers an opportunity to ask better questions:
- What regulated process does this software support?
- Which functions could affect product quality or regulatory records if they fail?
- Which functions are administrative or low risk?
- What level of testing is appropriate for each function?
- What evidence shows that the software performs as intended?
- How will changes be assessed, tested, approved, and released?
This is a better operating model than treating every click as equal.
Where manufacturers get CSA wrong
They start with the test script instead of intended use
A validation package should not begin with a pile of generic test cases. It should begin with intended use.
What does the software do in the regulated process? Does it route CAPA approvals? Calculate acceptance criteria? Control release status? Store complaint records? Maintain training requirements? Generate a regulatory report? Manage production parameters?
The intended use determines risk. Risk determines assurance. Assurance determines evidence.
They validate the platform but ignore the process
Software does not operate in isolation. A perfectly tested workflow can still fail if user roles are wrong, master data is uncontrolled, training is incomplete, records are not reviewed, or process ownership is unclear.
CSA should connect software assurance to the quality process the software supports. For example, a complaint system should be assessed in relation to complaint intake, investigation, MDR or vigilance evaluation, trend review, CAPA escalation, and record retention.
They over-test low-risk functions and under-test critical ones
A risk-based approach should create proportionality. A cosmetic dashboard filter may not require the same rigor as an automated release decision or a calculation used in product acceptance.
The goal is not to reduce discipline. The goal is to concentrate discipline where failure matters most.
They forget about configuration and change control
Most QMS and production software is configured. Workflows, roles, fields, forms, approval paths, reports, integrations, and notifications can all affect regulated outcomes.
A manufacturer needs a controlled way to assess configuration changes. Otherwise, a small admin update can quietly change a regulated process.
A practical CSA readiness check
Start with the software inventory. For each system used in production or the quality system, document:
- System name and owner
- Regulated process supported
- Intended use
- Critical functions
- Data integrity and record impact
- Interfaces and integrations
- User roles and access controls
- Supplier or vendor responsibility
- Change control process
- Assurance approach and evidence location
Then classify functions by risk. Focus especially on functions that:
- Make or support product acceptance decisions
- Control manufacturing or inspection steps
- Generate or preserve regulated records
- Route required approvals
- Calculate results or status
- Trigger reporting, escalation, or release decisions
- Affect data integrity, audit trails, or record retention
For high-risk functions, make sure testing is clear, objective, and tied to intended use. For lower-risk functions, use proportionate assurance methods such as unscripted testing, vendor evidence, configuration review, or targeted verification where appropriate.
What good looks like in practice
A mature CSA program makes regulated software easier to defend because the logic is clear.
The manufacturer can explain why the software is used, which functions matter most, how risk was assessed, what testing was performed, what evidence was retained, how users were trained, how changes are controlled, and how system performance is monitored.
That is especially powerful for an eQMS. If document control, training, CAPA, complaints, supplier quality, audits, management review, and change control all live in one connected platform, the company can reduce the number of disconnected systems that require separate validation, integration checks, data reconciliation, and audit defense.
Key takeaways
- CSA supports a risk-based approach to software used in medical device production and quality systems.
- Manufacturers should begin with intended use, not generic test scripts.
- Assurance effort should be proportional to the impact of software failure.
- Configuration, access, data integrity, supplier evidence, and change control are central to CSA.
- A connected compliance platform can reduce fragmentation and make software assurance easier to maintain.
How IntelaSolve helps
IntelaSolve gives life sciences teams one connected compliance infrastructure platform across regulatory, quality, production, post-market, and lifecycle workflows. By reducing reliance on disconnected point systems and spreadsheets, IntelaSolve helps manufacturers build a more controlled environment for regulated records, approvals, evidence, and quality decisions.
Request early access to IntelaSolve or complete the Compliance Readiness Analysis to identify where your production and quality software assurance program may be creating hidden compliance risk.